Recon: GSK prevails in Illinois Zantac suit; Baxter lifts forecast on strong device demand

• GSK wins latest trial over Zantac cancer claims (Reuters)
• Jeff Shuren stabilized the FDA’s medical devices center, winning over industry but not all patients (STAT)
• Baxter raises full-year profit forecast on robust demand for medical devices (Reuters)
• Harris’ running mate, Minnesota Governor Tim Walz, boasts progressive health care record (STAT)
• ‘Jerking families around’: Canceled Roche rare disease trial devastates parents, angers researchers (STAT)
• BioMarin scales back launch for hemophilia gene therapy, pitches path to profitability (Endpoints)
• What Washington wants in Cures 2.0 (Politico)

• China to beef up regulations on fentanyl chemicals, White House says (Reuters)
• India's Gland Pharma posts surprise fall in Q1 profit on soaring employee costs (Reuters)
• Sanofi: England Needs ‘Flexible’ Pricing For Multi-Indication Drugs (Pink Sheet)
• Japanese government grants Shinobi $59M for cell therapy development (Endpoints)
• Bayer details 3,200 job cuts so far, spotlights ‘momentum’ in pharma pipeline (Endpoints)

• Biotech VCs are pacing for another record-low year of fundraising amid glimpses of recovery (STAT)
• EU Helps Firms To Prioritize Submission Of Data On ‘Critical’ Drugs (Pink Sheet)
• Zoetis lifts 2024 results forecasts on strong demand for pet treatments (Reuters)
• Ex-Pfizer drug reduces osteoarthritis pain in British biotech's phase 2 study (Fierce)
• Former Biden White House health official joins Flagship Pioneering (STAT)
• Merck advances lung cancer attack, pocketing $170M from Daiichi and plotting ADC-trispecific combo (Fierce)
• Gaps Found In Most Pharma Trial Diversity Policies (Pink Sheet)
• Exclusive: Covid and epidemic threat biotech Aerium Therapeutics closes after emergence of variants (Endpoints)
• Ultimovacs’ cancer vaccine flunks again — this time in head and neck cancer (Endpoints)
• Eisai picks SEED Therapeutics for molecular glue deal worth as much as $1.5B (Endpoints)
• Bicycle Therapeutics focuses pipeline and streamlines leadership team (Endpoints)
• Hims takes steps to lock up drug supply for its booming weight loss business (Endpoints)
• Genentech partners with cash-strapped Sangamo on epigenetic Alzheimer’s therapy (Endpoints)

• FDA seeks feedback on health equity for medical devices (MedtechDive)
• Ascensia’s new head of CGM talks plans for a 365-day sensor (MedtechDive)
• J&J To Launch Velys Spine Platform After Securing FDA Clearance (MedtechInsight)

• Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims (Reuters)
• CooperSurgical Says Lab Hid Flawed IVF Product Tests (Law360)